The epidermal growth factor receptor (EGFR) signalling pathway contributes to a number of
processes important to tumour progression, including cell proliferation, apoptosis …

The epidermal growth factor (EGF) plays a role in the development of prostate cancer, which
becomes essential after androgen resistance has emerged. The EGF receptor (EGFR) is …

EGFR, highly expressed in a variety of human malignancies, is correlated with poor tumour
differentiation, high tumour growth and metastatic rate. EGF and several other ligands, such …

Purpose. To investigate the effects of the epidermal growth factor receptor tyrosine kinase
inhibitor (EGFR-TKI) ZD1839 ('Iressa') on the cellular proliferation of androgen-sensitive and …

The recent development of highly selective, target-based cancer therapeutics, such as
ZD1839 has resulted from a greater understanding of tumor biology. Amongst the most …

Growth factors regulate cellular proliferation and differentiation and are important in initiating
and maintaining neoplastic transformation. Cancer cells exhibit a decreased requirement for …

ZD1839 (Iressa; AstraZeneca Pharmaceuticals LP, Wilmington, DE) is an orally active,
selective inhibitor of epidermal growth factor receptor–tyrosine kinase (EGFR-TK) that blocks …

The erbB family of receptors, which includes the epidermal growth factor receptor, has been
widely implicated in promoting proliferation of malignant cells. The critical role played by …

The epidermal growth factor receptor (EGFR) signaling pathway plays an important role in a
number of processes that are key to tumor progression, including cell proliferation …

Purpose: These studies examined the effect of the epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor ZD1839 (“Iressa”) on CWR22 prostate tumors in nude mice. The …